Peter Hersey1. Show Affiliations » 1. Kolling Institute, and Melanoma Institute of Australia, University of Sydney, NSW 2065, Australia. Electronic address: peter.hersey@sydney.edu.au.
Abstract
Entities: Chemical Disease
Mesh： See more » Antineoplastic Agents/therapeutic useHumansIndoles/therapeutic useMelanoma/drug therapyMelanoma/secondaryMutationProtein Kinase Inhibitors/therapeutic useProto-Oncogene Proteins B-raf/antagonists & inhibitorsProto-Oncogene Proteins B-raf/geneticsSkin Neoplasms/drug therapySulfonamides/therapeutic useVemurafenib
Substances： See more » Antineoplastic AgentsIndolesProtein Kinase InhibitorsSulfonamidesVemurafenibBRAF protein, humanProto-Oncogene Proteins B-raf
Year: 2014 PMID： 24582506 DOI： 10.1016/S1470-2045(14)70079-8
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316